Can Augmentin (amoxicillin + clavulanate) cause ear problems such as otitis externa, ear pain, fullness, tinnitus, or hearing changes?

Augmentin Does Not Directly Cause Ear Problems

Augmentin (amoxicillin-clavulanate) does not cause ear issues such as otitis externa, ear pain, fullness, tinnitus, or hearing changes as a direct adverse effect of the medication. The FDA label for Augmentin does not list any ear-related adverse effects, and clinical trials in over 500 pediatric patients with acute otitis media reported no hearing changes or ear-related complications from the medication itself 1.

What the Evidence Shows

FDA-Approved Safety Data

The most comprehensive safety data comes from clinical trials of Augmentin ES-600 in 521 pediatric patients with acute otitis media. The most frequently reported adverse events were:

• Vomiting (6.9%)
• Fever (6.1%)
• Contact dermatitis/diaper rash (6.1%)
• Upper respiratory tract infection (4.0%)
• Diarrhea (3.8%)

Notably absent from this list are any ear-related symptoms 1. A comparative study of 450 pediatric patients found no statistically significant differences in adverse events between Augmentin formulations, and neither treatment significantly altered hearing acuity 1.

Theoretical Ototoxicity Concerns

While there is emerging case report data suggesting a possible association between amoxicillin and hearing loss (94 cases reported to the WHO global database, with 49 cases of deafness), this represents an extremely rare occurrence given the millions of prescriptions written annually 2. The median time to onset was 3 days, and in some cases hearing recovered after drug withdrawal 2. However, this evidence is of very low quality and requires further substantiation.

Important Clinical Context

When Ear Problems Occur During Augmentin Treatment

If a patient develops ear problems while taking Augmentin, consider these more likely explanations:

1. The underlying ear infection is not responding to treatment

• Augmentin may be ineffective against certain pathogens, particularly Pseudomonas aeruginosa, which causes 20-60% of acute otitis externa cases 3
• Treatment failure occurs in approximately 2.2% of children with acute otitis media treated with antibiotics 4

2. Allergic contact dermatitis from topical ear medications

• If the patient is using topical ear drops concurrently, neomycin-containing preparations cause contact sensitivity in 13-30% of patients with chronic otitis externa 3
• This presents as erythema, pruritus, edema, and persistent otorrhea 3

3. Fungal overgrowth after antibacterial therapy

• Fungi may overgrow in the ear canal after topical or systemic antibiotic use, causing persistent infection 3

4. Misdiagnosis or alternative pathology

• The original diagnosis may have been incorrect
• Other causes of otalgia include TMJ syndrome, dental pathology, or referred pain from head and neck sources 3

Clinical Recommendations

If a patient reports ear problems while taking Augmentin:

1. Reassess the diagnosis - Confirm whether the ear problem is new or represents treatment failure of the original condition
2. Examine for allergic contact dermatitis - Particularly if topical ear medications are being used concurrently
3. Consider culture - If symptoms persist, obtain a culture to identify resistant bacteria or fungal overgrowth 3
4. Evaluate for complications - Rule out serious complications like malignant otitis externa in high-risk patients (diabetics, immunocompromised) 3

Common Pitfall to Avoid

Do not automatically attribute new ear symptoms to Augmentin toxicity. The medication is being used to treat an ear infection, so worsening symptoms more likely represent treatment failure, inadequate pathogen coverage, or development of complications rather than a drug adverse effect.

When to Consider Drug-Related Hearing Loss

Only consider amoxicillin-related ototoxicity if:

• Hearing loss or tinnitus develops acutely (within 3 days of starting treatment)
• No other explanation exists (no middle ear effusion, no conductive hearing loss mechanism)
• Symptoms improve after drug discontinuation
• The patient has no other ototoxic exposures

Even then, this would be an exceptionally rare occurrence requiring specialist evaluation and reporting to pharmacovigilance systems 2.